First National Bank of Mount Dora Trust Investment Services boosted its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,238 shares of the biopharmaceutical company’s stock after buying an additional 50 shares during the quarter. First National Bank of Mount Dora Trust Investment Services’ holdings in Bristol-Myers Squibb were worth $514,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in BMY. Reilly Financial Advisors LLC lifted its holdings in Bristol-Myers Squibb by 4.4% during the 1st quarter. Reilly Financial Advisors LLC now owns 4,122 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 175 shares in the last quarter. Reliance Trust Co. of Delaware increased its position in Bristol-Myers Squibb by 0.4% during the 1st quarter. Reliance Trust Co. of Delaware now owns 62,903 shares of the biopharmaceutical company’s stock valued at $3,421,000 after purchasing an additional 264 shares during the period. Vicus Capital increased its position in Bristol-Myers Squibb by 2.3% during the 1st quarter. Vicus Capital now owns 6,086 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 139 shares during the period. Benson Investment Management Company Inc. purchased a new position in Bristol-Myers Squibb during the 1st quarter valued at about $2,220,000. Finally, DnB Asset Management AS increased its position in Bristol-Myers Squibb by 60.9% during the 1st quarter. DnB Asset Management AS now owns 474,006 shares of the biopharmaceutical company’s stock valued at $25,776,000 after purchasing an additional 179,500 shares during the period. Institutional investors own 68.80% of the company’s stock.

WARNING: “Bristol-Myers Squibb Company (BMY) Shares Bought by First National Bank of Mount Dora Trust Investment Services” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/15/bristol-myers-squibb-company-bmy-shares-bought-by-first-national-bank-of-mount-dora-trust-investment-services.html.

BMY has been the topic of a number of research reports. Jefferies Group LLC reissued a “buy” rating and set a $64.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, June 5th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 target price on the stock in a research report on Monday, June 5th. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, June 26th. Finally, Cowen and Company set a $65.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, July 10th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $62.66.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The stock was bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

Shares of Bristol-Myers Squibb Company (NYSE BMY) traded up 0.2050% on Friday, hitting $62.8185. 3,635,764 shares of the stock were exchanged. The stock has a market cap of $103.02 billion, a PE ratio of 22.9432 and a beta of 1.18. The company’s 50 day moving average is $58.32 and its 200-day moving average is $55.91. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $63.47. Bristol-Myers Squibb also was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 781 put options on the stock. This is an increase of approximately 117% compared to the typical daily volume of 360 put options.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.69 earnings per share. Analysts predict that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.49%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.